Aiming : Actualité Aiming en direct - P2 | Bourse Reflex
Accueil > Tags > Aiming

  • Toutes les actualités en rapport avec « Aiming »

28/04 18:35 Aiming - BUSINESS UPDATE - FIRST QUARTER 2016

26/04 18:35 Aiming - PUBLICATION OF THE 2015 ANNUAL FINANCIAL REPORT

26/04 07:00 Aiming - Revenue growth for Q1 across all divisions (+13.6%)

21/04 19:45 Aiming - PUBLICATION OF THE FIRST ISSUE OF GENTICEL'S SHAREHOLDER NEWSLETTER

20/04 18:30 Aiming - GENTICEL REPORTS ADDITIONAL RESULTS AT 12 MONTHS FROM PHASE 2 TRIAL OF HPV IMMUNOTHERAPEUTIC CANDIDATE, GTL001

06/04 18:00 Aiming - Disclosure of the total number of voting rights and shares composing the share capital

14/03 07:00 Aiming - GENTICEL ANNOUNCES 2015 ANNUAL RESULTS AND STRATEGIC UPDATE FOR 2016

10/03 18:30 Aiming - GENTICEL UPDATES ITS FINANCIAL CALENDAR FOR 2016 AND ANNOUNCES PARTICIPATION IN KEY CONFERENCES IN H1 2016

27/01 18:00 Aiming - Organic growth of 11.2% in the 4th quarter - 2015 revenues: EUR 273.8 million - Current operating margin target revised upwards

25/01 18:00 Aiming - BUSINESS UPDATE - FOURTH QUARTER 2015

11/01 08:30 Aiming - GENTICEL ANNOUNCES ITS FINANCIAL CALENDAR FOR 2016

07/01 18:00 Aiming - Disclosure of the total number of voting rights and shares composing the share capital

07/01 18:00 Aiming - SUMMARY OF GENTICEL'S LIQUIDITY CONTRACT WITH ODDO CORPORATE FINANCE

07/01 07:30 Aiming - GENTICEL TO EVALUATE ROCHE MOLECULAR SYSTEMS' COBAS(R) HPV TEST IN PREPARATION FOR PHASE 3 PROGRAM OF GTL001

05/01 19:00 Aiming - Genticel appoints Rémi Palmantier, PhD, as Chief Scientific Officer to accelerate its development

10/12 18:15 Aiming - Disclosure of the total number of voting rights and shares composing the share capital

02/12 18:00 Aiming - Benedikt Timmerman resumes CEO position at Genticel

24/11 18:00 Aiming - On the occasion of the 2015 edition of FUTUR40, Global EcoPower was awarded " Champion of Growth " by CroissancePlus and PME Finance

09/11 13:00 Aiming - FIRST-QUARTER 2015/16 REVENUE

29/10 18:00 Aiming - Genticel Announces First Patient Treated in U.S. Phase 1 Clinical Trial of GTL001, Company's Therapeutic Vaccine Candidate against HPV 16/18 Infections